Genetic analysis is now routine in metastatic non–small-cell lung cancer (NSCLC) to identify somatic sensitizing mutations in EGFR, typically L858R and exon 19 deletion (Ex19del). Patients with these genotypes are treated with first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (e.g., erlotinib, gefitinib, and afatinib) preferentially over chemotherapy owing to their marked superiority in tumor response, progression-free survival, and quality of life. Such molecular selection has seen median overall survival increase among patients with such genetic variants, from a median of 7.9 months in 2002¹ to 27.3 months in 2015.² However, despite rapid and durable responses, acquired . . .

中文翻译：

---

奥西替尼作为EGFR突变型非小细胞肺癌的一线治疗

现在，转移性非小细胞肺癌（NSCLC）常规进行遗传分析，以鉴定EGFR中的体细胞致敏突变，通常为L858R和外显子19缺失（Ex19del）。由于第一代或第二代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）在肿瘤反应方面的显着优越性（无进展），因此优先采用化学疗法治疗第一代或第二代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）（例如，厄洛替尼，吉非替尼和阿法替尼）生存和生活质量。这种分子的选择已经看到患者的这种基因变异中位总生存期增加，从7.9个月，中位数在2002年¹至27.3个月，2015年²然而，尽管快速和持久的反应，收购。。。